Doliprane divestiture and tripartite agreement: towards tighter control of foreign investment in France?
The sale of a controlling 50% stake in Opella, Sanofi’s €15 billion consumer healthcare subsidiary responsible for Doliprane, to the US investment fund Clayton, Dubilier & Rice (CD&R) has prompted a strategic response from the French state, and considerable controversy in France. Through Bpifrance, the French state would become a minority shareholder in Opella, holding…
Details
